Cargando…
Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis
BACKGROUND: Aldose reductase inhibitors (ARIs) can block the metabolism of the polyol pathway, and have been used to slow or reverse the progression of diabetic cardiovascular autonomic neuropathy (DCAN). The purpose of this study was to review the effectiveness and safety of ARIs in the treatment o...
Autores principales: | Hu, Xin, Li, Shengbing, Yang, Gangyi, Liu, Hua, Boden, Guenther, Li, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922720/ https://www.ncbi.nlm.nih.gov/pubmed/24533052 http://dx.doi.org/10.1371/journal.pone.0087096 |
Ejemplares similares
-
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008) -
In Search of Differential Inhibitors of Aldose Reductase
por: Balestri, Francesco, et al.
Publicado: (2022) -
Aldose Reductase Differential Inhibitors in Green Tea
por: Balestri, Francesco, et al.
Publicado: (2020) -
Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway
por: Mizukami, Hiroki, et al.
Publicado: (2020) -
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019)